Shared on 02 Nov 25
Fair value Increased 7.80%Travere Therapeutics' analyst price target increased from $35.71 to $38.50 per share, as analysts point to positive regulatory developments and continued strong prospects for Filspari, driving their upward revisions. Analyst Commentary Bullish Takeaways Bullish analysts highlight the cancellation of the FDA advisory committee meeting as a significant positive.
Shared on 04 Sep 25
Fair value Increased 3.73%FSGS And IgA Nephropathy Expansion Will Transform Market Reach
The consensus analyst price target for Travere Therapeutics has been raised to $35.71, reflecting strong Q2 results and robust demand growth for Filspari in IgAN, as well as optimism around upcoming FDA action dates and continued commercial execution. Analyst Commentary Expectations for meaningful upside driven by two near-term FDA action dates.
Shared on 01 May 25
Fair value Increased 0.47%